Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

• Other: Placebo
  Part 1: Placebo SC administration every 2 weeks X 10 weeks.
• Drug: ILV-094
  Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
• Drug: ILV-094
  Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
• Other: Placebo
  Part 2: Placebo SC administration every 2 weeks X 10 weeks
• Drug: ILV-094
  Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks

• Placebo Comparator: Arm 1
  Part 1: Placebo
  Intervention: Other: Placebo
• Experimental: Arm 2
  Part 1: 100 mg ILV-094 SC Q4W
  Intervention: Drug: ILV-094
• Experimental: Arm 3
  Part 1: 100 mg ILV-094 SC Q2W
  Intervention: Drug: ILV-094
• Placebo Comparator: Arm 4
  Intervention: Other: Placebo
• Experimental: Arm 5
  Part 2: 200 mg ILV-094 SC Q2W
  Intervention: Drug: ILV-094

Inclusion Criteria:

• Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening
• Active RA at the time of screening and baseline consisting of >= 5 swollen and >= 5 tender joints (28-joint count) and at least 1 of the following at screening: C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h
• Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (up to 25 mg weekly) for at least 8 weeks prior to the baseline visit.

Exclusion Criteria:

• Subjects with other rheumatic diseases
• Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamous cell carcinoma or in situ cervical cancer)
• Any prior use of B cell-depleting therapy